Introduction: The use of personal protective equipment can be burdensome and the risk of COVID-19 infection for this group is high. This study details to evaluate how prepared Health Care Workers consider themselves to be regarding the delivery of infection prevention and control procedures in their place of work. Method: This is a cross-sectional study conducted at Kathmandu Medical College Teaching Hospital in September 2020. A questionnaire was given to participants along with the information about the study. Service demand, skills, beliefs about capabilities, beliefs about consequences, intentions, environmental context and resources, social influences, emotion, WHO Wellbeing (over the last two weeks) were taken as dependent variables. Result: Out of 112 participants, 58(51.7%) were doctors and 54(48.3%) nurses; 65(58.1%) female and 47(41.9%) were male. The mean age was 31.2±4.1 y. Service demand was scored lowest (mean 0.7 out of 7) and beliefs about consequences were scored highest (mean 5.7 out of 7). Conclusion: Healthcare workers agreed that personal protective equipment at work is sufficiently effective to prevent the spread of COVID-19. They were not confident that the health care center at present can manage or can continue to manage the current patient surge related to COVID-19.
1 March 2023 in Journal of Kathmandu Medical College
Background: Ferric citrate is novel iron-based phosphate-binding drug for management of hyperphosphataemia and iron-deficiency anaemia in chronic kidney disease (CKD) patients. Objectives: To evaluate impact of ferric citrate therapy on reduction of phosphate levels and improvement in haematological parameters in CKD stages 3-5. Methods: This analytical, observational study was conducted at Kathmandu Medical College Teaching Hospital from 2020 July-December after ethical clearance using convenience sampling method. Non-dialysis dependent patients at CKD stages 3-5, having hyperphosphataemia (serum phosphate >=4.6mg/dL) and anaemia (serum haemoglobin <12 gm%, transferrin saturation <=30%, ferritin <=300ng/mL) were administered with 2gm twice daily dose of ferric citrate for 12 weeks and evaluated on outcomes in terms of reduction in serum phosphate levels and improvement in haematological parameters as study endpoints. Data were entered in Microsoft Excel and analysed in SPSS v.25. Significance level was set at p <0.05. Results: Of 84 study participants, majority had CKD stage 4 (46, 54.76%). A significant reduction (p <0.001) in mean serum phosphate levels of 6.21 ± 1.062 mg/dL from baseline to 4.89 ± 1.100 mg/dL in 12-weeks was observed. Patients with CKD stages 3, 4, and 5 had mean reduction of 1.67 (p = 0.005), 1.40 (p <0.001), and 1.04 mg/dL (p = 0.002) of serum Phosphate level respectively. Significant (p <0.001) improvements in hemoglobin level, serum iron, ferritin, total iron binding capacity, and transferrin saturation were reported. Conclusion: Ferric citrate is effective and well-tolerated phosphate-binder to improve hyperphosphataemia and iron deficiency anaemia in non-dialysis CKD stage 3, 4, and 5.